For nearly two decades, a researcher at the University of Windsor has been studying an unlikely candidate in the fight against cancer: dandelion root. What began as a handful of patient stories — people drinking dandelion tea and watching their cancer markers fall — has grown into a body of laboratory research substantial enough that even skeptical oncologists are paying attention. What it has not yet become is proof. That distinction matters, and it's worth sitting with both halves of the story.
How the Research Began
The formal investigation traces back to Siyaram Pandey, a biochemist who was initially doubtful when an oncologist colleague, Dr. Caroline Hamm, told him about patients whose cancer markers had dropped after drinking dandelion root tea. Pandey's own background was in purified plant compounds with established anticancer activity — dandelion tea, brewed at home from an unstandardized source, was a harder thing to test. His solution was to create a controlled, reproducible extract in the lab so it could actually be studied.
The project carried personal weight from the start. It was seeded by a donation from the parents of a young man who died from infections caused by a chemotherapy-compromised immune system — not from the cancer itself. They wanted research into alternatives that wouldn't carry that same cost.
What Pandey found in that first experiment surprised him: the extract killed leukemia cells rapidly and consistently in the lab, while leaving healthy cells untouched. That selectivity — targeting cancer cells while sparing normal ones — is the detail that has kept researchers interested ever since.
What the Lab Studies Show
Over the following years, Pandey's team and others published peer-reviewed studies testing dandelion root extract across multiple cancer types. In melanoma cells, a notoriously treatment-resistant cancer, the extract triggered cell death within 48 hours. In leukemia cells, the effect was dose- and time-dependent — more extract and more time meant more cancer cell death. In colorectal cancer cells, it eliminated 95 percent of cells within two days. Similar effects appeared in pancreatic cancer cells, and in mouse models of prostate cancer, oral extract slowed tumor growth and enhanced chemotherapy's effectiveness. Other research groups have reported comparable results in breast cancer, including triple-negative breast cancer, one of the most aggressive and hardest-to-treat forms of the disease.
The proposed mechanism isn't a single pathway but several acting together: the extract appears to trigger programmed cell death, disrupt the energy-producing mitochondria inside cancer cells, increase oxidative stress, and activate a process that causes cancer cells to break down beyond recovery. Researchers believe the selectivity for cancer cells over healthy ones may trace back to structural differences in the mitochondria themselves — though the full explanation is still being worked out.
Why Lab Results Aren't the Same as Clinical Proof
This is the part of the story that deserves as much attention as the promising results. Dr. Prasanth Reddy, a medical oncologist, described the preclinical findings as credible and biologically plausible — the kind of early signal that commonly prompts further drug development. But he was equally clear about the limits: "Many compounds — including natural products and synthetic drugs — demonstrate impressive anticancer activity in vitro but ultimately fail to show meaningful benefit in human clinical trials."
Dandelion root extract has not yet completed a human clinical trial. It cleared an early regulatory hurdle when Health Canada approved a Phase 1 trial for blood cancers in 2012, but that trial was ultimately halted due to low enrollment and funding loss — not because of safety concerns. Pandey is currently working to secure funding for a new trial. In the meantime, what exists is a strong preclinical case and a set of documented patient outcomes — Pandey has collected 162 case reports of patients with end-stage cancers who used the extract on their own and recovered — but case reports, however compelling, are not a substitute for a controlled trial.
Reddy's guidance for patients and clinicians is worth repeating plainly: lab findings should be treated as hypothesis-generating, not as grounds for changing clinical practice on their own. Integrative approaches like this one can be considered alongside conventional care when they have supportive evidence and a good safety profile — but as an adjunct, not a replacement, unless stronger clinical evidence eventually says otherwise. Anyone considering a botanical product during cancer treatment should loop in their oncology team, since interactions with standard therapies are possible.
Why This Kind of Story Matters
Surveys suggest most cancer patients already want this conversation: one 2023 survey found 60 percent of patients strongly believe in complementary therapies, and more than 70 percent want access to them within their care. Reddy's own view is that oncology training would benefit from more grounding in evidence-based integrative approaches, so physicians can have informed, balanced conversations rather than dismissing the question outright — and that these conversations are often most useful earlier, not just after standard options run out.
That's really the heart of integrative practice: taking promising, biologically plausible research seriously enough to keep pursuing it rigorously, while being honest about exactly how much — and how little — we currently know. Dandelion root extract may or may not eventually earn a place in oncology care. Right now, it stands as a genuinely interesting research thread, not a verdict.
"I know that I know nothing." — Socrates